HBC Amgen Lecture Series: Lecture 6 - The Clinical Path of an AD Therapeutic  


Wednesday, April 24, 2019, 5:00pm to 6:00pm


Cannon Room, HMS Campus

"The Biotechnology Edge”

Insights from Lab Bench to Patient Bedside



The Clinical Path of an AD Therapeutic  

April 24th, 2019
5:00 - 6:00pm
Cannon Room, HMS

Food will be provided!


Speaker: Vissia Viglietta, MD, PhD

Dr Viglietta is a Global Development Leader and Global Product General Manager at Amgen. She is leading the late stage development of the BACE inhibitor CNP520 for the prevention of Alzheimer’s disease and the TREM2 program for AD. Her major research interest has been in elucidating the role of autoreactive T cells and regulatory cells in autoimmune diseases such as multiple sclerosis.